13F-HR filed by ARCH Venture Management, LLC
ARCH Venture Management, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:41:32 UTC, with 17 holding rows worth $1,613,349,389.
- Accession
- 0001012975-26-001080
- Filer
- CIK 1274403
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 17 entries on the cover page, a total value of $1,613,349,389 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,613,349,389 with VALUE read as dollars as filed, 13F file number 028-19358. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| KARDIGAN INC | 485925101 | CMN | 15,042,036 | $221,870,031 | dollars as filed | |
| PARABILIS MEDICINES INC COM | 698955101 | Stock | 6,412,780 | $207,068,666 | dollars as filed | |
| VIR BIOTECHNOLOGY INC | 92764N102 | COM | 12,694,163 | $141,920,742 | dollars as filed | |
| SANA BIOTECHNOLOGY INC | 799566104 | COM | 45,860,681 | $133,683,885 | dollars as filed | |
| SEAPORT THERAPEUTICS INC | 81221K108 | COMMON STOCK | 6,294,951 | $126,969,162 | dollars as filed | |
| RAPPORT THERAPEUTICS INC COM | 75383L102 | Stock | 3,728,738 | $125,285,597 | dollars as filed | |
| SCHOLAR ROCK HLDG CORP | 80706P103 | COM | 2,345,711 | $113,344,756 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 4,120,053 | $111,983,041 | dollars as filed | |
| BEAM THERAPEUTICS INC | 07373V105 | COM | 4,540,132 | $111,006,227 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 7,091,557 | $103,962,226 | dollars as filed | |
| 908 DEVICES INC COM | 65443P102 | Stock | 5,725,045 | $70,647,055 | dollars as filed | |
| PRIME MEDICINE INC | 74168J101 | COM | 18,486,894 | $56,477,461 | dollars as filed | |
| LYELL IMMUNOPHARMA INC COM NEW | 55083R203 | Stock | 3,247,162 | $31,789,716 | dollars as filed | |
| GENERATE BIOMEDICINES INC | 370920100 | COMMON STOCK | 1,944,426 | $29,205,294 | dollars as filed | |
| NEUMORA THERAPEUTICS INC. | 640979100 | COM | 33,847,838 | $20,180,081 | dollars as filed | |
| BOUNDLESS BIO INC | 10170A100 | COM | 2,694,095 | $6,762,178 | dollars as filed | |
| Gossamer Bio, Inc. | 38341P201 | Common Stock, $0.0001 par value per share | 100,698 | $1,193,271 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-26-001080 | this filing | 2026-11-16 |